Microbial biomarkers in transplantation and related methods

HK40137374APending Publication Date: 2026-09-11KARIUS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124818
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-28
Filing Date
2026-06-15
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure provides methods and systems for detecting active microbial infection. In some cases, the methods can be used to detect active infection in a recipient of a transplanted organ, graft, or medical device. The present disclosure provides a method of monitoring disease in a human subject, wherein the method comprises obtaining a biological sample from the human subject; measuring concentrations of microbial cell-free nucleic acid (mcfNA) in the biological sample; comparing sequencing coverage near the origin of replication of a microbe to coverage in later replicating regions to derive a peak-to-trough ratio (PTR) score; and based at least on the PTR score, determining a rate of replication of the microbe. The methods described herein may analyze fragment lengths.
Need to check novelty before this filing date? Find Prior Art

Description

Abstract This disclosure provides methods and systems for detecting active microbial infections. In some cases, these methods can be used to detect active infections in recipients of organs, grafts, or medical devices. This disclosure provides a method for monitoring human disease, comprising: obtaining a biological sample from a human body; measuring the concentration of cell-free microbial nucleic acid (mcfNA) in the biological sample; comparing sequencing coverage near the origin of microbial replication with coverage of subsequent replication regions to obtain a peak-to-trough ratio (PTR) value; and determining the microbial replication rate based at least on the PTR value. The methods described herein can analyze fragment lengths.

Claims

CLAIMSWHAT IS CLAIMED IS:

1. A method of identifying active replication of a microbe in a human subject, wherein the method comprises:(a) providing a biological sample from the human subject, wherein the microbe is present in the human subject or suspected of being present in the human subject;(b) performing massively parallel sequencing on cell-free nucleic acids (cfNA) in the biological sample to generate microbial cell-free nucleic acid (mcfNA) sequence reads;(c) aligning the mcfNA sequence reads with a reference sequence containing sequences within an origin of replication region of the microbial genome to determine coverage of the mcfNA within the origin of replication region of the microbial genome; and(d) determining whether the microbe is actively replicating in the human subject based on the coverage of the mcfNA within the origin of replication region of the microbial genome.

2. The method of claim 1, further comprising comparing the coverage of the mcfNA within the origin of replication region of the microbial genome to coverage in a later replicating region of the microbial genome to derive a peak-to-trough ratio (PTR) score.

3. The method of claim 2, wherein the determining in (d) comprises using the PTR score to determine whether the microbe is actively replicating in the human subject.

4. The method of any one of claims 1-3, wherein the massively parallel sequencing is whole genome sequencing.

5. The method of any one of claims 1-4, wherein the massively parallel sequencing is Next Generation Sequencing.

6. The method of claim 5, wherein the Next Generation Sequencing is Next Next Generation sequencing.

7. The method of any one of claims 1-6, further comprising determining a concentration or quantity of the mcfNA.

8. The method of claim 7, further comprising monitoring the concentration or quantity of the mcfNA over time.

9. The method of any one of claims 1-8, further comprising identifying fragments of mcfNA that vary during a course of treatment.

10. The method of claim 9, wherein the fragments of mcfNA are within the origin of replication region of the microbial genome and span the origin of replication or are within the origin of replication region but do not span the origin of replication.

11. The method of any one of claims 1-10, wherein sequences within the origin of replication region of the microbial genome are within 0.5 kb, 1 kb, 1.5 kb, 2 kb, 5 kb, 8 kb, 10 kb, 15 kb, 20 kb, 25 kb, 30 kb or 50 kb of either side of the origin of replication and wherein the sequences either span or do not span the origin of replication.

12. The method of any one of claims 2-11, wherein the later replicating region is a region greater than 50 kb, 75 kb, 100 kb, or 150 kb from either side of the origin of replication.

13. The method of any one of claims 2-12, wherein the later replicating region is a region within 0.5 kb, 1 kb, 1.5 kb, 2 kb, 5 kb, 8 kb, 10 kb, 15 kb, 20 kb, 25 kb, 30 kb or 50 kb of one or more replication termini and wherein the later replicating region either spans or does not span a replication terminus.

14. The method of any one of claims 2-13, wherein active replication is identified when coverage within the origin of replication region of the microbial genome and coverage at a later replicating region are statistically different from each other and wherein the coverage at the origin of replication region of the microbial genome is higher compared to the coverage at the later replicating region.

15. The method of any one of claims 3-13, wherein the PTR score is a statistically significant score and wherein active replication is identified when the PTR score is greater than 1.

16. The method of any one of claims 3-13, wherein the PTR score is a statistically significant score and wherein active replication is identified when the PTR score is greater than 1.2.

17. The method of any one of claims 3-13, wherein the PTR score is a statistically significant score and wherein coverage at the origin of replication region of the microbial genome is greater than two reads and the coverage at the later replicating region is greater than two reads.

18. The method of any one of claims 3-16, wherein active replication is monitored by detecting statistically significant PTR scores over time.

19. The method of any one of claims 3-16, wherein a worsening infection is identified when a magnitude of statistically significant PTR scores increases over a period of at least two days.

20. The method of any one of claims 3-16, wherein a worsening infection is identified when a magnitude of statistically significant PTR scores increases over a period of at least five days.

21. The method of any one of claims 3-19, wherein a worsening infection is identified when a magnitude of statistically significant PTR scores increases by at least two-fold over a period of 10 days.

22. The method of any one of claims 3-19, wherein a worsening infection is identified when the PTR score increases in a statistically significant manner over a period of at least 5 days.

23. The method of any one of claims 1-22, wherein the human subject is a transplant recipient.

24. The method of any one of claims 1-23, wherein the human subject is a xenotransplant recipient.

25. The method of claim 24, wherein the human subject is a transplant recipient of a non-human mammalian organ or graft, a pig organ or graft, or a bovine organ or graft.

26. The method of any one of claims 24-25, wherein the xenotransplant is selected from the group consisting of: a pig heart, a pig liver, a pig lungs, pig kidney, bovine kidney, bovine liver, bovine lungs, non-human mammalian heart, non-human mammalian liver, and non-human mammalian lungs.

27. The method of any one of claims 1-26, wherein the microbe is a bacterium or virus associated with a transplanted organ or graft or with a xenotransplanted organ or graft.

28. The method of any one of claims 1-27, wherein the microbe is a virus.

29. The method of claim 28, wherein the virus is a DNA virus.

30. The method of claim 28, wherein the virus is an enveloped virus.

31. The method of any one of claims 1-30, wherein the microbe is a virus selected from EBV, CMV, HSV, and HTLV.

32. The method of any one of claims 1-31, wherein the virus is a double-stranded DNA virus.

33. The method of claim 32, wherein the virus is in the order Herpesvirales.

34. The method of claim 32, wherein the virus is a cytomegalovirus (CMV).

35. The method of claim 32, wherein the virus is porcine CMV (pCMV).

36. The method of any one of claims 1-35, wherein the cell-free nucleic acids are cfDNA.

37. The method of any one of claims 1-36, wherein the mcfNA comprises microbial DNA.

38. The method of any one of claims 1-37, wherein the mcfNA comprises microbial RNA.

39. The method of any one of claims 7-38, wherein the measuring concentrations of mcfNA in the biological sample comprises preparing a nucleic acid library.

40. The method of any one of claims 1-39, further comprising measuring lengths of nucleic acid fragments at the origin of replication region of the microbial genome.

41. The method of any one of claims 1-40, further comprising determining gene strand bias of the bottom and top strands at the origin of replication region of the microbial genome.

42. The method of any one of claims 1-41, further comprising measuring fluctuations in fragment populations over time following treatment.

43. The method of any one of claims 1-42, further comprising measuring fluctuations in the amount of ~55 nt or -140 nt fragments of mcfDNA.

44. The method of any one of claims 1-43, further comprising measuring relative abundance of reads from -55 nt population of microbial mcfNA.

45. The method of any one of claims 1-44, further comprising measuring fluctuations in the amount of mcfDNA from short, ssDNA-derived mcfDNA fragments.

46. The method of any one of claims 14-45, further comprising producing and sequencing DNA libraries, and aligning sequence reads to a reference genome of the transplant.

47. The method of any one of claims 1-46, further comprising aligning sequence reads to a genome of a microbe.

48. The method of claim 47, further comprising aligning sequence reads to a genome of a bacterium.

49. The method of claim 48, further comprising aligning sequence reads to a genome of a virus.

50. The method of claim 49, further comprising aligning sequence reads to a CMV genome.

51. The method of any one of claims 1-50, further comprising measuring principal components (PCs) of longest contiguous reads.

52. The method of claim 51, further comprising comparing PCs to a PTR score.

53. The method of any one of claims 1-52, further comprising identifying a disease, disorder, or condition in the human subject wherein the disease, disorder, or condition is selected from the group consisting of: xenograft injury, transplant rejection, active viral infection, and latent viral infection.

54. The method of any one of claims 1-53, further comprising administering a treatment to the human subject to treat a microbial infection identified by the method.

55. The method of claim 54, wherein the treatment is an antiviral drug.

56. The method of claim 54 or 55, further comprising monitoring a response to the treatment, wherein the response to the treatment is monitored by performing massively parallel sequencing on cell-free nucleic acids (cfNA) in a biological sample collected after the administering a treatment to the human subject in order to generate microbial cell -free nucleic acid (mcfNA) sequence reads; aligning the mcfNA sequence reads with a reference sequence containing sequences near an origin of replication of the microbe to determine coverage of the mcfNA near the origin of replication; and determining whether the microbe is actively replicating in the human subject based on the coverage of the mcfNA near the origin of replication.

57. The method of claim 55 or 56, wherein the antiviral drug is an antiviral, an abacavir, an acyclovir (aciclovir), an adefovir, an amantadine, an ampligen, an amprenavir (agenerase), anumifenovir (arbidol), an atazanavir, an atripla (efavirenz / emtricitabine / tenofovir), a baloxavir marboxil (xofluza), a biktarvy (bictegravir / emtricitabine / tenofovir alafenamide), a boceprevir, a bulevirtide, a cidofovir, a cobicistat (tybost), a combivir (lamivudine / zidovudine), a daclatasvir (daklinza), a darunavir, a delavirdine, a descovy (emtricitabine / tenofovir alafenamide), a didanosine, a docosanol, a dolutegravir, a doravirine (pifeltro), an edoxudine, an efavirenz, an elvitegravir, an emtricitabine, an enfuvirtide, an ensitrelvir, an entecavir, an etravirine (intelence), a famciclovir, a fomivirsen, a fosamprenavir, a foscarnet, a ganciclovir (cytovene), an ibacitabine, an ibalizumab (trogarzo), an idoxuridine, an imiquimod, an inosine pranobex, an indinavir, a lamivudine, a letermovir (prevymis), a lopinavir, a loviride, a maraviroc, a methisazone, a moroxydine, a nelfinavir, a nirmatrelvir / ritonavir (paxlovid), a nevirapine, a nitazoxanide, a norvir, an oseltamivir (tamiflu), a penciclovir, a peramivir, a penciclovir, a peramivir (rapivab), a pleconaril, a podophyllotoxin, a raltegravir, a remdesivir, a ribavirin, a rilpivirine (edurant), a rilpivirine, a rimantadine, a ritonavir, a saquinavir, a simeprevir (olysio), a sofosbuvir, a stavudine, a taribavirin (viramidine), a telaprevir, a telbivudine (tyzeka), a tenofovir alafenamide, a tenofovir disoproxil, a tipranavir, a trifluridine, a trizivir, a tromantadine, a truvada, an umifenovir, a valaciclovir (valtrex), a valganciclovir (valcyte), a vicriviroc, a vidarabine, a zalcitabine, a zanamivir (relenza), a zidovudine, a stereoisomer of any of these, a salt of any of these, or any combination thereof.

58. The method of any one of claims 14-57, wherein the method further comprises detecting donor-derived cell -free DNA in the transplant recipient in order to detect transplant rejection.

59. The method of claim 58, further comprising administering an immunosuppressant drug to the transplant recipient to treat the transplant rejection.

60. The method of any one of claims 1-59, wherein the biological sample is a biological fluid sample.

61. The method of claim 60, wherein the biological fluid sample is a cell-free biological fluid sample.

62. The method of claim 61, wherein the biological fluid sample is a plasma sample, a serum sample, a blood sample, a saliva sample, a synovial fluid sample, a cerebrospinal fluid sample, or a urine sample.

63. The method of claim 62, wherein the biological fluid sample is a plasma sample.

64. A method of using a quantity of sequence reads at an origin of replication region of a microbial genome to determine whether a subject has an active infection, the method comprising:(a) providing a plasma or serum sample comprising microbial cell free nucleic acids from a subject;(b) performing massively parallel sequencing on the microbial cell-free nucleic acids to obtain sequence reads associated with a microbe;(c) detecting a coverage bias of sequence reads covering a genomic locus at the origin of replication region of the microbial genome; and(d) determining whether there is active replication of the microbe at least in part from the presence or absence of the coverage bias, wherein the active replication of the microbe is associated with an infection of an internal solid organ.

65. A method of detecting whether an organ transplant recipient has an active infection, the method comprising:(a) providing sequence data from the organ transplant recipient, wherein the sequence data comprises sequence reads created from sequencing a sample from the organ transplant recipient, wherein the sample comprises a plurality of microbial cell-free DNA fragments of different lengths;(b) analyzing the sequence data to determine a profile of the microbial cell-free DNA fragments of different lengths;(c) modeling the microbial cell-free DNA fragments as a set of normal distributions with medians at a first fragment length and a second fragment length, wherein the first fragment length is shorter than the second fragment length; and(d) identifying an active infection when the normal distribution with the median at the first fragment length constitutes greater than 20% of all fragments of microbial cell-free DNA in the sample.

66. The method of claim 65, wherein the normal distribution with the median at the first fragment length has a median fragment length of about 55 nt.

67. The method of claim 65, wherein the normal distribution with the median at the second fragment length has a median fragment length of about 140 nt.

68. The method of claim 65, further comprising identifying a normal distribution with a median at a third fragment length, wherein the third fragment length is about 90 nt.

69. The method of claim 65, wherein the normal distribution with the median at the first fragment length has a median fragment length of at least 30 nt.

70. The method of any one of claims claim 65-69, wherein the normal distribution with the median at the first fragment length has a median fragment length of at most 80 nt.

71. The method of any one of claims claim 65-70, wherein the normal distribution with the median at the first fragment length has a median fragment length of at least 40 nt.

72. The method of any one of claims claim 65-71, wherein the normal distribution with the median at the first fragment length has a median fragment length of at most 65 nt.

73. The method of any one of claims claim 65-72, wherein an active infection is identified when the normal distribution with the median at the first fragment length constitutes greater than 30% of all fragments of microbial cell-free DNA in the sample.

74. The method of any one of claims claim 65-73, wherein an active infection is identified when the normal distribution with the median at the first fragment length constitutes greater than 50% of all fragments of microbial cell-free DNA in the sample.

75. A method of detecting whether an organ transplant recipient has an active infection, the method comprising:(a) providing sequence data from the organ transplant recipient, wherein the sequence data comprises sequence reads created from sequencing a sample from the organ transplant recipient, wherein the sample comprises a plurality of microbial cell-free DNA fragments of different lengths;(b) analyzing the sequence data to determine a profile of the microbial cell-free DNA fragments of different lengths;(c) modeling the microbial cell-free DNA fragments as a composite of three distinct Gaussian distributions predetermined to have median lengths of about 55 nt, about 90 nt, and about 140 nt; and(d) identifying an active infection when the Gaussian distribution with the median length of 55 nt constitutes greater than 20% of all fragments of microbial cell-free DNA in the sample.

76. A method of detecting an actively replicating microbe in a human subject, the method comprising:(a) providing a biological sample comprising microbial cell-free nucleic acids from a human subject;(b) contacting the microbial cell-free nucleic acids with primers specific for the replicating microbe, wherein the primers are designed to produce amplicons that span at least a portion of an origin of replication region of a microbial genome; and(c) subjecting the microbial cell-free nucleic acids to a quantitative polymerase chain reaction (qPCR) using the primers specific for the replicating microbe, thereby detecting actively replicating microbe in the human subject.

77. The method of claim 76, wherein the nucleic acids are cell-free DNA.

78. The method of claim 76 or 77, wherein the actively replicating virus is CMV.

79. The method of any one of claims 76-78, further comprising comparing (i) the coverage of the plurality of sequence reads for the origin of replication region to (ii) the coverage of the plurality of sequence reads for later replicating regions to derive a peak-to-trough ratio (PTR) score.

80. The methods of any one of claims 64-79, wherein the median of the fragment lengths is between 30-80 nt, 40-65 nt, or 45-70 nt.

81. A method of detecting an alteration in a prosthetic device that has been implanted in a subject, the method comprising:(a) providing a biological sample from a subject;(b) sequencing cell-free nucleic acids (cfNA) from the biological sample to generate sequence data comprising a plurality of sequence reads for microbial cell-free DNA fragments;(c) processing the sequence data to determine a coverage of the plurality of sequence reads for an origin of replication region and a coverage of the plurality of sequence reads for a later replicating region; and(d) based at least on the coverage of the plurality of sequence reads for the origin of replication region and the coverage of the plurality of sequence reads for the later replicating region, identifying an alteration in the prosthetic device, wherein the alteration in the prosthetic device is a microbial infection associated with the prosthetic device.

82. The method of claim 81, further comprising comparing (i) the coverage of the plurality of sequence reads for the origin of replication region to (ii) the coverage of the plurality of sequence reads for a later replicating region to derive a peak-to-trough ratio (PTR) score.

83. The method of claim 81 or 82, further comprising administering a treatment to the human subject to treat the microbial infection associated with the prosthetic device.

84. The method of claim 83, wherein the microbial infection is a bacterial infection.

85. The method of claim 84, wherein the treatment is an antibacterial drug or antibiotic.

86. The method of any one of claims 81-85, further comprising monitoring a response to the treatment, wherein the response to the treatment is monitored by performing massively parallel sequencing on cell-free nucleic acids (cfNA) in a biological sample collected after the administering a treatment to the human subject in order to generate microbial cell-free nucleic acid (mcfNA) sequence reads; aligning the mcfNA sequence reads with a reference sequence containing sequences within an origin of replication region of the microbial genome to determine coverage of the mcfNA within the origin of replication region; and determiningwhether the microbe is actively replicating in the human subject based on the coverage of the mcfNA within the origin of replication region of the microbial genome.

87. The method of any one of claims 84-86, wherein the microbe is a Staphylococcus bacterium or Nocardia bacterium.

88. A method of detecting an alteration in a prosthetic device that has been implanted in a subject, the method comprising:(a) providing a biological sample from the subject;(b) sequencing cell-free nucleic acids (cfNA) from the biological sample to generate sequence data, wherein the sequence data comprises a plurality of sequence reads for microbial cell-free DNA fragments of different lengths;(c) processing the sequence data to determine a profile of microbial cell-free DNA fragment lengths in the sample; and(d) based at least on the profile of microbial cell-free DNA fragment lengths in the sample, identifying an alteration in the prosthetic device, wherein the alteration is a microbial infection associated with the prosthetic device.

89. The method of claim 88, wherein the method further comprises modeling the microbial cell- free DNA fragments as a set of normal distributions with medians at a first fragment length and a second fragment length, wherein the first fragment length is shorter than the second fragment length; and identifying an active infection when the normal distribution with the median at the first fragment length constitutes greater than 20% of all fragments of microbial cell-free DNA in the sample.

90. The method of claim 88, wherein the median at the first fragment length is about 55 nt.

91. The method of claim 88, wherein the median at the second fragment length is about 90 nt.

92. The method of claim 88, further comprising identifying a normal distribution with a median at a third fragment length, wherein the third fragment length is about 140 nt.

93. The method of any one of claims 88-92, further comprising administering an antibiotic drug to the subject when actively replicating bacteria are detected.

94. The method of any one of claims 81-93, wherein the prosthetic device is made entirely of non-biological materials.

95. The method of any one of claims 81-93, wherein the prosthetic device is partially made of biological material and partially made of non-biological materials.

96. The method of any one of claims 81-95, wherein the prosthetic device is a prosthetic heart valve.

97. The method of any one of claims 81-96, wherein the prosthetic device is a prosthetic heart valve that comprises porcine tissue.

98. The method of any one of claims 81-97, wherein the prosthetic device comprises a metal, titanium, cobalt, pyrolytic carbon, or a polymer.